搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
oncnursingnews
21 小时
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
oncnursingnews
23 小时
NKT2152 Shows Promising Efficacy in Advanced Clear Cell Kidney Cancer
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
oncnursingnews
1 天
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
oncnursingnews
1 天
Todd Shryock
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews
1 天
Alyson Moadel-Robblee, PhD
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews
1 天
Kathleen Keenan, NP
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews
1 天
Danielle Hicks
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews
1 天
Kelly Hylton, MSN, FNP-C
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews
2 天
Nivolumab With or Without Ipilimumab Sustains 10-Year Survival Benefit in Advanced Melanoma
Nivolumab (Opdivo), when given alone or in combination with ipilimumab (Yervoy), led to significant benefit in 10-year ...
oncnursingnews
2 天
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations ...
oncnursingnews
2 天
Breastfeeding Is OK During Endocrine Therapy Break for HR+ Breast Cancer
Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈